March 18, 2022
Fresenius nominates Dr. Christoph Zindel for Supervisory Board
The Supervisory Board of Fresenius SE & Co. KGaA will propose that the next Annual General Meeting on May 13, 2022 elect Dr. Christoph Zindel, 60, to the Supervisory Board. If elected, he will also join the Supervisory Board’s Audit Committee. As announced last year, Klaus-Peter Müller, 77, will leave the Supervisory Board at the end of the Annual General Meeting and turn over the Audit Committee’s chairmanship to Susanne Zeidler, 61. The next regular election of all shareholder representatives is scheduled for the 2025 Annual General Meeting.
Dr. Zindel has been a member of the Siemens Healthineers Managing Board since October 2019. He began his career as a practicing physician in surgery, internal medicine and nuclear medicine, before moving into the healthcare industry in 1998 as a Segment Manager at Siemens Healthcare. There he held various management positions in the magnetic resonance-tomography business division. After three years in the U.S., lastly as head of the Business Unit Hematology and Urinanalysis at Beckman Coulter in Miami, he returned to Siemens Healthineers in 2015 and headed the Business Line Magnetic Resonance. In 2018, Dr. Zindel was appointed President Diagnostic Imaging.
Klaus-Peter Müller has been a Member of the Supervisory Board of Fresenius SE (today Fresenius SE & Co. KGaA) and its Audit Committee since 2008. From 2010 until 2021 he also belonged to the Supervisory Board of Fresenius Management SE. A highly regarded financial expert, Klaus-Peter Müller worked at Commerzbank AG from 1966 to 2008 and served from 2001 to 2008 as Chief Executive Officer.
Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, said: “Dr. Christoph Zindel has a background in medicine, extensive international experience and comprehensive knowledge of the healthcare industry. This makes him an outstanding addition to our Board. As for Klaus-Peter Müller, on behalf of the Supervisory Board I want to thank him for his long connection with Fresenius and his many important contributions to our success.”
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.